Know Labs - KNW STOCK NEWS

Know Labs (KNWN) has announced a 1-for-40 reverse stock split of its common stock, effective February 19, 2025. The company's stock will temporarily trade under 'KNWND' for 20 days before reverting to 'KNWN' on the OTC Pink Market. This move follows the company's delisting from NYSE American due to bid prices falling below $0.10.

The company is currently appealing the delisting decision to the NYSE American Listings Qualifications Panel, with trading suspended during the appeal process. The reverse split was implemented by the Board of Directors as part of efforts to regain NYSE American listing compliance. The company expects near-term revenues from its recently announced Know Labs Technology Licensing initiative while continuing its focus on blood glucose monitoring development.

Know Labs (KNWN) reported Q1 FY2025 financial results, showing a net loss of $4.67 million, up 35.4% from $3.45 million in Q1 FY2024. The company recorded a non-cash charge of $2.45 million related to stock-based compensation, debt extinguishment, warrant repricing, and debt issuance costs.

R&D expenses decreased 46.1% to $802,000, while SG&A expenses dropped 2% to $1.97 million. Cash and equivalents stood at $1.03 million as of December 31, 2024, down from $3.11 million on September 30, 2024. The company closed a $300,000 registered direct offering and believes it has sufficient funds to operate until April 30, 2025.

Shareholder equity was negative $3.91 million, and the company's auditors included a going concern warning in their opinion.

Know Labs (KNWN) has announced it will host a webcast on February 14, 2025, at 1:30 PM PT to discuss its first quarter fiscal year 2025 business updates and financial results for the period ended December 31, 2024. The company, which recently moved from NYSE American to OTC Markets, specializes in radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and has launched the Know Labs Technology Licensing (KTL) initiative.

The live audio webcast will be accessible to media and investors at https://ir.knowlabs.co starting at 1:15 PM PT, with a replay available afterward on the company's website.

Know Labs (KNWN) has filed an appeal against NYSE American's decision to delist the company due to its stock price falling below $0.10. During the appeal process, trading of Know Labs stock on NYSE American will be suspended, and the company has transitioned to trading on the OTC Markets under the symbol 'KNWN' effective January 29, 2025.

The company, which specializes in radio frequency dielectric spectroscopy (RFDS), recently initiated a licensing program through Know Labs Technology Licensing (KTL) and continues to advance its proprietary technology. Their primary focus remains on developing non-invasive diagnostics, particularly blood glucose monitoring, which will require FDA clearance before market introduction.

CEO Ron Erickson emphasized that despite the NYSE situation, the company has successfully reduced overhead, received peer-reviewed recognition, and maintains optimism about near-term licensing opportunities and revenue generation.

Know Labs (NYSE American: KNW) announced that NYSE Regulation is initiating delisting proceedings due to the company's bid price falling under $.10, according to Section 1003(f)(v) of the NYSE American Company Guide. The company's stock will be suspended from NYSE American trading while Know Labs works on compliance measures and appeals the delisting determination.

Effective January 29, 2025, the company's stock will trade on the OTC Markets under the symbol 'KNWN'. CEO Ron Erickson emphasized that this development comes at a time when the company has initiated a licensing program, received peer-reviewed recognition, reduced overhead, and continued advancing its proprietary radio frequency dielectric spectroscopy (RFDS) technology. The company maintains its focus on developing non-invasive diagnostics, particularly blood glucose monitoring.

Know Labs (NYSE: KNW) has announced the formation of Know Labs Technology Licensing (KTL), a new business unit dedicated to licensing its radio frequency dielectric spectroscopy (RFDS) technology. Modeled after Qualcomm Technology Licensing, KTL aims to expand the application of RFDS beyond medical diagnostics into various industries including industrial processes, consumer electronics, automotive, and IoT networks.

The initiative emerged following significant third-party interest after the company's Skunkworks announcement in May 2024. KTL will provide Software Development Kits and RFDS test automation products to licensing partners. An early example includes the development of a 'smart steering wheel' for automotive safety applications.

While Know Labs maintains its focus on non-invasive medical diagnostics, particularly blood glucose monitoring, KTL will enable external partners to integrate RFDS technology across different sectors, potentially creating new revenue streams through licensing agreements.

Know Labs (NYSE: KNW) has announced a registered direct offering priced at-the-market, raising $300,000 in gross proceeds before deducting fees and expenses. The offering consists of units, each comprising one share of stock and one warrant at $0.24 per unit. The warrants are exercisable at $0.24 and will expire after five years, featuring a cashless exercise option under certain circumstances.

The offering is being conducted under the company's effective shelf registration statement on Form S-3, which was filed with the SEC on December 22, 2023, and declared effective on January 11, 2024. A prospectus supplement dated December 13, 2024, has been filed to complement the base prospectus.

Know Labs (NYSE American: KNW) announced that NYSE American has accepted its compliance plan on December 10, 2024. The company has been granted until March 27, 2026 to regain compliance with the exchange's listing standards under Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide. During this period, KNW will undergo periodic reviews to assess progress with the plan's initiatives. The company's shares will continue trading on NYSE American, subject to meeting other listing requirements. If KNW fails to regain compliance by the deadline or show sufficient progress, NYSE American may initiate delisting proceedings. This development doesn't affect KNW's business operations or SEC reporting obligations.

Know Labs (NYSE American: KNW) released its FY2024 10-K annual report, addressing shareholder concerns about its going concern audit opinion. The company reported a $16 million net loss, including $5 million in non-cash charges. Key achievements include: development of 2nd generation KnowU™ CGM, completion of companion mobile app, filing of 68 new patents (total 332 active patents), and clinical studies showing 93% accuracy in glycemic level determination. The company reduced monthly cash burn by 42% to $700,000 and initiated strategic projects including a Smart Steering Wheel initiative. Management expressed confidence in accessing capital through their effective S-3 shelf offering to continue operations.